NRC Health — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; compared with the corresponding 2022 periods. Amounts below are in U.S. dollars; financial statement figures are converted to millions unless otherwise noted.
Business context and results
NRC Health provides analytics and insights to healthcare organizations, primarily through renewable subscription services. Its offerings address patient and employee experience, engagement, reputation, and related areas. Subscription revenue is generally recognized over the contract period; agreements are typically cancelable on short or no notice without penalty.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $37.9m | $37.7m | $110.6m | $113.4m |
| Operating income | $10.0m | $11.1m | $28.3m | $34.3m |
| Operating margin | 26.2% | 29.5% | 25.6% | 30.2% |
| Net income | $7.9m | $8.3m | $22.1m | $25.2m |
| Diluted EPS | $0.32 | $0.33 | $0.89 | $1.00 |
| Cash from operations | Not separately stated | Not separately stated | $26.4m | $28.2m |
Financial position, cash flow, and capital allocation
- At September 30, cash and cash equivalents were $3.8m, down from $25.0m at December 31, 2022. Current assets were $24.7m and current liabilities $40.8m, resulting in a $16.1m working-capital deficit, versus a $10.3m surplus at year-end.
- Cash from operations of $26.4m was down 6.2% year over year. Investing activities used $12.0m, mainly for property, equipment, software, and building improvements. Financing activities used $35.6m.
- The company paid $33.4m in dividends during the first nine months, including $24.6m for a special $1.00-per-share dividend declared and paid in September. It also repurchased $4.1m of shares during the period. A further $2.9m quarterly dividend was declared in Q3 and paid in October.
- Term-loan principal was $18.9m, with a 5% fixed rate and monthly payments through May 2027. The company also had $5.0m drawn on its $30m revolving facility, leaving $25m available; the revolver rate was 7.66% at quarter-end and maturity is May 2025. The $75m delayed-draw facility had not been used and is limited to permitted acquisitions or share repurchases.
- The company reported compliance with its financial covenants. It cited minimum fixed-charge coverage of 1.10x and a maximum cash-flow leverage ratio of 3.00x. The credit agreement is secured by substantially all assets.
Changes versus the prior comparable period
- Q3 revenue rose 0.7%, but nine-month revenue fell 2.5%. The year-to-date decrease reflected lower U.S. revenue and the closure of the Canadian office, which eliminated $0.8m of prior-year revenue; management does not expect future Canadian revenue.
- For the first nine months, U.S. recurring revenue from existing clients declined $1.1m, including $0.4m related to eliminating a non-core solution; recurring revenue from new customer sales declined $1.2m. Non-recurring revenue increased $0.2m.
- Nine-month recurring contract value was $144.3m, down 2.5%. Management attributed the decline to its focus on core digital solutions and weaker new-client sales.
- Operating income declined 10.4% in Q3 and 17.4% year to date. SG&A and depreciation and amortization increased, weighing on margins; nine-month direct expenses declined modestly.
- Q3 SG&A growth included increased marketing, sales and client-support costs, legal fees, cybersecurity, and software services. Year-to-date marketing initiatives increased $2.6m; lower innovation investment and building-demolition costs partly offset the increase.
Outlook, risks, and unusual items
- The filing provides no specific revenue, earnings, or margin guidance. Management said it expects future other income and expense to decline as money-market investments decrease and interest expense rises with revolver borrowings.
- Management estimated remaining headquarters renovation costs of $2.6m in 2023 and $12.3m in 2024, expected to be funded through operating cash flows and revolver borrowings. Cash capital expenditures were $12.0m in the first nine months.
- Management believes cash, borrowing availability, and operating cash flow will be sufficient for projected capital and debt needs for the foreseeable future, while noting the decline in cash and working capital associated largely with dividends and repurchases.
- Key stated risks include client non-renewals or reduced purchases, competition and price pressure, economic downturn, healthcare-industry consolidation and regulatory changes, staffing, technology or platform failures, and cybersecurity events. The company also cited potential effects from global conflicts and disease outbreaks.
- Ordinary-course claims and litigation were reported; management does not believe their disposition will materially adversely affect financial position, results, or liquidity. The filing does not quantify a material litigation contingency.
- The company had $1.8m of gross unrecognized tax benefits. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported for the quarter.
Important facts for investors to verify
- Whether recurring contract value and new-client sales stabilize, and whether existing-client attrition continues.
- How the special dividend, ongoing dividends, repurchases, and renovation spending affect cash, working capital, and reliance on the revolving credit facility.
- Renovation spending against the stated estimate, and the impact of borrowing costs and reduced money-market balances on future earnings.
- Compliance with credit covenants and the terms governing dividends, share repurchases, and use of the delayed-draw facility.
- Whether the company’s expectation of adequate liquidity remains supportable given its $16.1m working-capital deficit and $3.8m cash balance.